PROPIONIC ACID | TERIC GN9 | PROPYLENE GLYCOL | UNKNOWN 8 - Resultados da pesquisa

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx flx 700 ph adjuster and penetrating surfactant

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade pro 700 surfactant

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sacoa cohort 700 surfactant

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agricrop spraybuff 700 surfactant

sipcam pacific australia pty. limited - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - control of penetration | reduce alkaline hydrolysis | wetting agent (use as directed) | improve penetrating properties

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dermaclens cream

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm collide 700 adjuvant

nufarm australia limited - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

macspred acidifier surfactant

macspred pty. ltd. - soyal phospholipids; propionic acid - dispersible concentrate - soyal phospholipids ungrouped active 350.0 g/l; propionic acid acid-general active 350.0 g/l - surfactant

Estados Unidos - inglês - NLM (National Library of Medicine)

carbaglu- carglumic acid tablet, for suspension

recordati rare diseases - carglumic acid (unii: 5l0hb4v1ew) (carglumic acid - unii:5l0hb4v1ew) - carbaglu is indicated in adult and pediatric patients as: - adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to nags deficiency. - maintenance therapy for the treatment of chronic hyperammonemia due to nags deficiency. carbaglu is indicated in adult and pediatric patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to pa or mma. none pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women with nags deficiency exposed to carbaglu. if carbaglu is administered during pregnancy, health care providers should report carbaglu exposure by calling 1-888-575-8344. risk summary although rare case reports of carbaglu use in pregnant women are insufficient to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, untreated nags deficiency, pa and mma can result in irreversible neurologic damage and death in pregnant women (see clinical considerations). in an animal reproduction study, decreased survival and growth occurred in offspring born to rats that received carglumic acid at a dose approximately 38 times the maximum reported human maintenance dose. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, miscarriage, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with urea cycle disorders, pa, and mma may experience an increase in catabolic stress which can trigger a hyperammonemic crisis both in the intrapartum and in the post-partum (3-14 days post-partum) periods. maternal complications related to hyperammonemic crisis can include neurological impairment, coma and in some cases death. data animal data no effects on embryo-fetal development were observed in pregnant rats treated with up to 2000 mg/kg/day (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on auc [area under the plasma concentration-time curve]) from two weeks prior to mating through organogenesis or in pregnant rabbits treated with up to 1000 mg/kg/day (approximately 6 times the maximum reported human maintenance dose [100 mg/kg/day] based on auc) during organogenesis. in a pre- and post-natal developmental study, female rats received oral carglumic acid from organogenesis through lactation at doses of 500 mg/kg/day and 2000 mg/kg/day. decreased growth of offspring was observed at 500 mg/kg/day and higher (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on auc), and reduction in offspring survival during lactation was observed at 2000 mg/kg/day (approximately 38 times the maximum reported human maintenance dose [100 mg/kg/day] based on auc). no effects on physical and sexual development, learning and memory, or reproductive performance were observed through maturation of the surviving offspring at maternal doses up to 2000 mg/kg/day. the high dose (2000 mg/kg/day) produced maternal toxicity (impaired weight gain and approximately 10% mortality). risk summary it is not known whether carglumic acid is present in human milk. there are no available data on the effects of carglumic acid on the breastfed infant or the effects on milk production. carglumic acid is present in milk from treated rats. when a drug is present in animal milk, it is likely that the drug will be present in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for carbaglu and any potential adverse effects on the breastfed child from carbaglu or from the underlying maternal condition. the safety and effectiveness of carbaglu for the treatment of pediatric patients (birth to 17 years of age) with acute or chronic hyperammonemia due to nags deficiency and acute hyperammonemia due to pa or mma have been established, and the information on these uses are discussed throughout the labeling. there are insufficient data to determine if there is a difference in clinical or biochemical responses between adult and pediatric patients treated with carbaglu. clinical studies of carbaglu did not include patients 65 years of age and older to determine whether they respond differently from younger patients. plasma concentrations of carglumic acid increased in patients with renal impairment [see clinical pharmacology (12.3)] . reduce the carbaglu dosage in patients with moderate or severe renal impairment [see dosage and administration (2.4)]. the pharmacokinetics of carglumic acid have not been evaluated in patients with end stage renal disease.

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

buff-it spray adjuvant

victorian chemical company proprietary limited - propionic acid; triethanolamine; non-ionic fatty acid ethoxylates and glycerides - soluble concentrate - propionic acid acid-general active 383.0 g/l; triethanolamine amine/amide active 192.0 g/l; non-ionic fatty acid ethoxylates and glycerides emulsifiers & surfactants active 545.0 g/l - adjuvant - fungicide additive | herbicide additive | insecticide additive | activator | additive | penetrant | post emergent herbicide | sp - reduce alkaline hydrolysis | spreader spray (refer to directions) | wetting agent (use as directed) | improve penetrating properties

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

ibuprofen 200mg soft capsules

pfizer healthcare ireland - ibuprofen - capsule, soft - 200 milligram(s) - propionic acid derivatives; ibuprofen